• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症中的继发性发作性运动障碍:临床-影像学特征和治疗。七例患者的病例报告。

Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.

机构信息

Department of Neurology, Pontificia Universidad Católica de Chile, Hospital Sótero del Río, Santiago, Chile.

Department of Neurology, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Mult Scler. 2017 Nov;23(13):1791-1795. doi: 10.1177/1352458517702968. Epub 2017 Apr 11.

DOI:10.1177/1352458517702968
PMID:28397579
Abstract

Secondary paroxysmal dyskinesias (SPDs) are short, episodic, and recurrent movement disorders, classically related to multiple sclerosis (MS). Carbamazepine is effective, but with risk of adverse reactions. We identified 7 patients with SPD among 457 MS patients (1.53%). SPD occurred in face ( n = 1), leg ( n = 2), or arm +leg ( n = 4) several times during the day. Magnetic resonance imaging (MRI) showed new or enhancing lesions in thalamus ( n = 1), mesencephalic tegmentum ( n = 1), and cerebellar peduncles ( n = 5). Patients were treated with clonazepam and then acetazolamide ( n = 1), acetazolamide ( n = 5), or levetiracetam ( n = 1) with response within hours (acetazolamide) to days (levetiracetam). No recurrences or adverse events were reported after a median follow-up of 33 months.

摘要

继发性发作性运动障碍(SPD)是一种短暂、间歇性和复发性运动障碍,通常与多发性硬化症(MS)有关。卡马西平有效,但有不良反应的风险。我们在 457 名 MS 患者中发现了 7 名 SPD 患者(1.53%)。SPD 在一天中多次发生在面部(n=1)、腿部(n=2)或手臂+腿部(n=4)。磁共振成像(MRI)显示丘脑(n=1)、中脑被盖(n=1)和小脑脚(n=5)有新的或强化病变。患者接受氯硝西泮治疗,然后接受乙酰唑胺(n=1)、乙酰唑胺(n=5)或左乙拉西坦(n=1)治疗,数小时(乙酰唑胺)至数天(左乙拉西坦)内有反应。在中位随访 33 个月后,没有复发或不良反应报告。

相似文献

1
Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.多发性硬化症中的继发性发作性运动障碍:临床-影像学特征和治疗。七例患者的病例报告。
Mult Scler. 2017 Nov;23(13):1791-1795. doi: 10.1177/1352458517702968. Epub 2017 Apr 11.
2
Levetiracetam-responding paroxysmal nonkinesigenic dyskinesia.左乙拉西坦反应性阵发性非运动诱发性运动障碍
Clin Neuropharmacol. 2007 Jul-Aug;30(4):241-4. doi: 10.1097/wnf.0b013e31803b9415.
3
Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia.吡拉西坦和左乙拉西坦这两种吡咯烷酮衍生物,在阵发性肌张力障碍的仓鼠模型中发挥抗肌张力障碍活性。
Eur J Pharmacol. 2000 Mar 17;391(3):251-4. doi: 10.1016/s0014-2999(00)00105-9.
4
Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.多发性硬化症中的发作性运动诱发性运动障碍样表型。
Mult Scler. 2017 Nov;23(13):1795-1797. doi: 10.1177/1352458517702535. Epub 2017 Apr 11.
5
Paroxysmal dystonia and paroxysmal tremor in a young patient with multiple sclerosis.一名年轻多发性硬化症患者的阵发性肌张力障碍和阵发性震颤
Ital J Neurol Sci. 1995 Jun;16(5):315-9. doi: 10.1007/BF02249107.
6
Paroxysmal dystonia with thalamic lesion in multiple sclerosis.多发性硬化症伴丘脑病变的阵发性肌张力障碍
Neurol Sci. 2001 Oct;22(5):391-4. doi: 10.1007/s100720100070.
7
Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam.
Eur J Neurol. 2009 Jun;16(6):e112-3. doi: 10.1111/j.1468-1331.2007.01783.x. Epub 2008 Apr 22.
8
Phenotypic characterization of PIGN-associated paroxysmal dyskinesia in Soft-coated wheaten terriers and preliminary response to acetazolamide therapy.软毛淡黄色梗犬中与 PIGN 相关的发作性运动障碍的表型特征及乙酰唑胺治疗的初步反应
Vet J. 2021 Mar;269:105606. doi: 10.1016/j.tvjl.2021.105606. Epub 2021 Jan 6.
9
Successful treatment of paroxysmal ataxia and dysarthria in multiple sclerosis with levetiracetam.左乙拉西坦治疗多发性硬化症伴阵发性共济失调和构音障碍的疗效观察。
Mult Scler Relat Disord. 2016 Nov;10:79-81. doi: 10.1016/j.msard.2016.09.003. Epub 2016 Sep 9.
10
[Paroxysmal dystonia and multiple sclerosis].[阵发性肌张力障碍与多发性硬化症]
Rev Neurol (Paris). 2014 Feb;170(2):119-23. doi: 10.1016/j.neurol.2013.07.031. Epub 2013 Nov 20.

引用本文的文献

1
Movement Disorder in Demyelinating Disease: Tracing the Charcot's Foot Print.脱髓鞘疾病中的运动障碍:追寻夏科氏足迹
Ann Indian Acad Neurol. 2022 Sep-Oct;25(5):821-831. doi: 10.4103/aian.aian_64_22. Epub 2022 Jun 8.
2
Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide.多发性硬化相关的发作性运动诱发性运动障碍:对拉科酰胺的长期良好反应。
J Mov Disord. 2022 Sep;15(3):286-289. doi: 10.14802/jmd.22016. Epub 2022 Jul 26.
3
Movement Disorders in Multiple Sclerosis: An Update.多发性硬化症中的运动障碍:最新进展。
Tremor Other Hyperkinet Mov (N Y). 2022 May 4;12:14. doi: 10.5334/tohm.671. eCollection 2022.
4
Secondary Paroxysmal Dyskinesia as a Presenting Symptom of Multiple Sclerosis.继发性发作性运动障碍作为多发性硬化症的首发症状
Mov Disord Clin Pract. 2019 Apr 19;6(5):406-408. doi: 10.1002/mdc3.12764. eCollection 2019 Jun.
5
Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in China.中国专家关于发作性运动诱发性运动障碍的诊断与治疗建议:专家共识
Transl Neurodegener. 2021 Feb 16;10(1):7. doi: 10.1186/s40035-021-00231-8.
6
Paroxysmal Symptoms in Multiple Sclerosis-A Review of the Literature.多发性硬化症的阵发性症状——文献综述
J Clin Med. 2020 Sep 25;9(10):3100. doi: 10.3390/jcm9103100.
7
Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias.发作性运动障碍和发作性共济失调的临床和遗传概述。
Int J Mol Sci. 2020 May 20;21(10):3603. doi: 10.3390/ijms21103603.
8
Clinical Features and Treatment in the Spectrum of Paroxysmal Dyskinesias: An Observational Study in South-West Castilla y Leon, Spain.发作性运动障碍谱系的临床特征与治疗:西班牙卡斯蒂利亚-莱昂西南部的一项观察性研究
Neurol Res Int. 2019 May 2;2019:4191796. doi: 10.1155/2019/4191796. eCollection 2019.
9
Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.多发性硬化症继发发作性运动障碍的病灶相关性。
J Neurol. 2018 Oct;265(10):2277-2283. doi: 10.1007/s00415-018-8989-2. Epub 2018 Jul 31.